On November 5, 2020, Ocuphire Pharma, Inc., formerly known as Rexahn Pharmaceuticals, Inc. (the ‘Company’), completed its business combination with the private entity formerly known as Ocuphire Pharma, Inc. (‘Ocuphire’), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended on June 29, 2020 (the ‘Merger Agreement’), by and among the Company, Ocuphire and Razor Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (‘Merger Sub’), pursuant to which, among other matters, Merger Sub merged with and into Ocuphire, with Ocuphire continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger (the ‘Merger’). In accordance with the Merger Agreement, on November 5, 2020, the employment of the Company’s Chief Executive Officer, Mr. Douglas Swirsky terminated immediately following the effectiveness of the Merger. The Board has appointed Mina Sooch as the Company’s Chief Executive Officer effective November 6, 2020.